# Coronavirus (COVID-19) ACEi/ARB Investigation

Study · id `cardio:ct-nct04330300` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04330300](<https://clinicaltrials.gov/study/NCT04330300>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04330300

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 2414 participants.

## Technical summary

Registry record NCT04330300. Randomized; no masking; primary purpose prevention. Start 2020-04-30 (actual); primary completion 2021-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 2414 participants (planned count; ClinicalTrials.gov record NCT04330300, source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)
- Started: 2020-04-30 (actual) (ClinicalTrials.gov record NCT04330300, source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)
- Primary completion: 2021-07-31 (anticipated) (ClinicalTrials.gov record NCT04330300, source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)
- Completion: 2021-12-01 (anticipated) (ClinicalTrials.gov record NCT04330300, source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)
- Countries: Ireland (ClinicalTrials.gov record NCT04330300, source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04330300-2020-06-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Coronavirus (COVID-19) ACEi/ARB Investigation
- Acronym: CORONACION
- Condition: Hypertension
- Condition: COVID-19
- Intervention (Drug): Thiazide or Thiazide-like diuretics
- Intervention (Drug): Calcium Channel Blockers
- Intervention (Drug): ACE inhibitor
- Intervention (Drug): Angiotensin receptor blocker
- Lead sponsor: National University of Ireland, Galway, Ireland
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Calcium channel blockers (`cardio:calcium-channel-blockers`)
- Registry intervention name matches this record: ACE inhibitors (`cardio:ace-inhibitors`)
- Registry intervention name matches this record: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: National University of Ireland, Galway, Ireland (`cardio:org-national-university-of-ireland-galway-ireland`)

## Provenance

Content hash: fb8fb1f119c3ebeaae0d603467e42708663e1a0e2d6ac485e36e344662427f79
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
